Alternatives to overcoming bacterial resistances: State-of-the-art

Microbiological Research

Volumn 191, Issue , 2016, Pages 51-80

  Rios, Alessandra C ^a   Moutinho, Carla G ^b,c   Pinto, Flávio C ^c   Del Fiol, Fernando S ^a   Jozala, Angela ^a   Chaud, Marco V ^a   Vila, Marta M D C ^a   Teixeira, José A ^b   Balcão, Victor M ^a,b  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Alternatives to conventional antibiotics; Antibiotics; Antibodies and vaccines; Antimicrobial peptides and bacteriocins; Bacterial resistance; Bacteriophages and phage therapy; Lysin therapy

Indexed keywords

ANTIBIOTICS; ANTIBODIES; ANTIMICROBIAL AGENTS; BACTERIA; BACTERIOPHAGES; CHEMICAL ANALYSIS; MACHINERY; PEPTIDES; POLYPEPTIDES; VACCINES;

ANTIMICROBIAL PEPTIDE; ANTIMICROBIAL THERAPY; BACTERIAL RESISTANCE; BACTERIOCINS; GRAM-POSITIVE BACTERIUM; LYSIN THERAPY; PHAGE THERAPY; THERAPEUTIC POTENTIALS;

CHEMICAL RESISTANCE;

ANTIBIOTICS; ANTIBODY; ANTIMICROBIAL ACTIVITY; BACTERIOPHAGE; BACTERIUM; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; EUKARYOTE; PEPTIDE; PUBLIC HEALTH; VACCINE;

BACTERIA (MICROORGANISMS); EUKARYOTA; POSIBACTERIA;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; HUMAN; MEDICAL RESEARCH; MICROBIOLOGY; PROCEDURES; TRENDS;

BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; BIOMEDICAL RESEARCH; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84974624028     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2016.04.008     Document Type: Review

References (250)

1. Łeski T.A., Tomasz A. Role of Penicillin-Binding Protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. J. Bacteriol. 2005, 187(5):1815-1824.
2. Aarestrup F.M., Agerso Y., Gerner-Smidt P., Madsen M., Jensen L.B. Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagn. Microbiol. Infect. Dis. 2000, 37(2):127-137.
3. Aarestrup F.M. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2015, 370(1670):20140085.
4. Abedon S.T., Kuhl S.J., Blasdel B.G., Kutter E.M. Phage treatment of human infections. Bacteriophage 2011, 1(2):66-85.
5. Abhilash M., Vidya A.G., Jagadevi T. Bacteriophage therapy: a war against antibiotic resistant bacteria. Internet J. Altern. Med. 2009, 7(1):e17744.
6. Abraham E.P., Chain E. An enzyme from bacteria able to destroy penicillin. Rev. Infect. Dis. 1988, 10(4):677-678. 1940.
7. Ackermann H.W. 5500 Phages examined in the electron microscope. Arch. Virol 2007, 152(2):227-243.
8. Almeida A., Cunha A., Gomes N.C.M., Alves E., Costa L., Faustino M.A.F. Phage therapy and photodynamic therapy: low environmental impact approaches to inactivate microorganisms in fish farming plants. Mar. Drugs 2009, 7(3):268-313.
9. Amer L.S., Bishop B.M., van Hoek M.L. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem. Biophys. Res. Commun. 2010, 396(2):246-251.
10. Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol. 2010, 1(134):1-7.
11. Atterbury R.J. Bacteriophage biocontrol in animals and meat products. Microb. Biotechnol. 2009, 2(6):601-612.
12. Balcão V.M., Vila M.M.D.C. Structural and functional stabilization of protein entities: state-of-the-art. Adv. Drug Deliv. Rev. 2015, 93:25-41.
13. Balogh B., Jones J.B., Iriarte F.B., Momol M.T. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 2010, 11(1):48-57.
14. Baltzer S.A., Brown M.H. Antimicrobial peptides-promising alternatives to conventional antibiotics. J. Mol. Microbiol. Biotechnol. 2011, 20(4):228-235.
15. Balu S., Reljic R., Lewis M.J., Pleass R.J., McIntosh R., van Kooten C., van Egmond M., Challacombe S., Woof J.M., Ivanyi J. A novel human IgA monoclonal antibody protects against tuberculosis. J. Immunol. 2011, 186(5):3113-3119.
16. Bebbington C., Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr. Opin. Biotechnol. 2008, 19(6):613-619.
17. Begley M., Hill C., Ross R.P. Tolerance of Listeria monocytogenes to cell envelope-acting antimicrobial agents is dependent on SigB. Appl. Environ. Microbiol. 2006, 72(3):2231-2234.
18. Bencivengo A.-M., Cudic M., Hoffmann R., Otvos L. The efficacy of the antibacterial peptide, pyrrhocoricin, is finely regulated by its amino acid residues and active domains. Lett. Pept. Sci. 2001, 8(3-5):201-209.
19. Bernbom N., Jelle B., Brogren C.H., Vogensen F.K., Nørrung B., Licht T.R. Pediocin PA-1 and a pediocin producing Lactobacillus plantarum strain do not change the HMA rat microbiota. Int. J. Food Microbiol. 2009, 130(3):251-257.
20. Björn C., Håkansson J., Myhrman E., Sjöstrand V., Haug T., Lindgren K., Blencke H.M., Stensvåg K., Mahlapuu M. Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin, Strongylocentrotus droebachiensis. AMB Express 2012, 2(1):67-78.
21. Bodaszewska-Lubas M., Brzychczy-Wloch M., Gosiewski T., Heczko P.B. Antibacterial activity of selected standard strains of lactic acid bacteria producing bacteriocins-pilot study. Postepy Hig. Med. Dosw. 2012, 66:787-794.
22. Boerlin P., Reid-Smith R.J. Antimicrobial resistance: its emergence and transmission. Anim. Health Res. Rev. 2008, 9(2):115-126.
23. Borysowski J., Weber-Dabrowska B., Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med. 2006, 231(4):366-377.
24. Brady R.A., Mocca C.P., Prabhakara R., Plaut R.D., Shirtliff M.E., Merkel T.J., Burns D.L. Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection. PLoS One 2013, 8(4):e63040.
25. Brand A.M., Kwaadsteniet M., Dicks L.M. The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett. Appl. Microbiol. 2010, 51(6):645-649.
26. Brandenburg L.O., Merres J., Albrecht L.J., Varoga D., Pufe T. Antimicrobial peptides: multifunctional drugs for different applications. Polymers 2012, 4(1):539-560.
27. Bruhn O., Grötzinger J., Cascorbi I., Jung S. Antimicrobial peptides and proteins of the horse - insights into a well-armed organism. Vet. Res. 2011, 42(1):98-119.
28. Buchholz U., Bernard H., Werber D., Böhmer M.M., Remschmidt C., Wilking H., Deleré Y., an der Heiden M., Adlhoch C., Dreesman J., Ehlers J., Ethelberg S., Faber M., Frank C., Fricke G., Greiner M., Höhle M., Ivarsson S., Jark U., Kirchner M., Koch J., Krause G., Luber P., Rosner B., Stark K., Kühne M. German outbreak of Escherichia coli 0104:H4 associated with sprouts. N. Engl. J. Med. 2011, 365(19):1763-1770.
29. Burton J.P., Chilcott C.N., Moore C.J., Speiser G., Tagg J.R. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J. Appl. Microbiol. 2006, 100(4):754-764.
30. Burton J.P., Wescombe P.A., Moore C., Chilcott C.N., Tagg J.R. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl. Environ. Microbiol. 2006, 72(4):3050-3053.
31. Burton J.P., Wescombe P.A., Macklaim J.M., Chai M.H., Macdonald K., Hale J.D., Tagg J., Reid G., Gloor G.B., Cadieux P.A. Persistence of the oral probiotic Streptococcus salivarius M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics. PLoS One 2013, 8(6):e65991.
32. Campos J., Ferech M., Lázaro E., de Abajo F., Oteo J., Stephens P., Goossens H. Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. J. Antimicrob. Chemother. 2007, 60(3):698-701.
33. Cao L., Dai C., Li J., Fan Z., Song Y., Wu Y., Cao Z., Li W. Antibacterial activity and mechanism of a scorpion venom peptide derivative in vitro and in vivo. PLoS One 2012, 7(7):e40135.
34. Carlet J., Mainardi J.L. Antibacterial agents: back to the future. Can we live with only colistin, co-trimoxazole and fosfomycin?. Clin. Microbiol. Infect. 2012, 18(1):1-3.
35. Carlet J., Collignon P., Goldmann D., Goossens H., Gyssens I.C., Harbarth S., Jarlier V., Levy S.B., N'Doye B., Pittet D., Richtmann R., Seto W.H., van der Meer J.W., Voss A. Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378(9788):369-371.
36. Carlet J., Jarlier V., Harbarth S., Voss A., Goossens H., Pittet D. Ready for a world without antibiotics? The Pensières antibiotic resistance call to action. Antimicrob. Resist. Infect. Control 2012, 1(1):11-23.
37. Carlet J., Rambaud C., Pulcini C. WAAR (World Alliance against Antibiotic Resistance): safeguarding antibiotics. Antimicrob. Resist. Infect. Control 2012, 1(1):25-30.
38. Carmody L.A., Gill J.J., Summer E.J., Sajjan U.S., Gonzalez C.F., Young R.F., LiPuma J.J. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 2009, 201(2):264-271.
39. Celia L.K., Nelson D., Kerr D.E. Characterisation of a bacteriophage lysin (Ply700) from Streptococcus uberis. Vet. Microbiol. 2007, 130(1-2):107-117.
40. Chan B.K., Abedon S.T. Phage therapy pharmacology phage cocktails. Advances in Applied Microbiology 2012, vol. 78:1-23. Elsevier Academic Press Inc., San Diego.
41. Charan J., Mulla S., Ryavanki S., Kantharia N. New Delhi Metallo-beta lactamase-1 containing enterobacteriaceae: origin, diagnosis, treatment and public health concern. Pan Afr. Med. J. 2012, 11:22-28.
42. Chen Y., Cao L., Zhong M., Zhang Y., Han C., Li Q., Yang J., Zhou D., Shi W., He B., Liu F., Yu J., Sun Y., Cao Y., Li Y., Li W., Guo D., Cao Z., Yan H. Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. PLoS One 2012, 7(4):e34947.
43. Cheng Q., Nelson D., Zhu S., Fischetti V.A. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 2005, 49(1):111-117.
44. Chhibber S., Kaur S., Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 2008, 57(12):1508-1513.
45. Chibani-Chennoufi S., Bruttin A., Dillmann M.-L., Brüssow H. Phage-Host interaction: an ecological perspective. J. Bacteriol. 2004, 186(12):3677-3686.
46. Cho J., Hwang I.S., Choi H., Hwang J.H., Hwang J.S., Lee D.G. The novel biological action of antimicrobial peptides via apoptosis induction. J. Microbiol. Biotechnol. 2012, 22(11):1457-1466.
47. Cirioni O., Ghiselli R., Silvestri C., Kamysz W., Orlando F., Mocchegiani F., Di Matteo F., Riva A., Lukasiak J., Scalise G., Saba V., Giacometti A. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother. 2007, 51(6):2005-2010.
48. Collins B., Curtis N., Cotter P.D., Hill C., Ross R.P. The ABC transporter AnrAB contributes to the innate resistence of Listeria monocytogenes to nisin, bacitracin and various beta-lactam antibiotics. Antimicrob. Agents Chemother. 2010, 54(10):4416-4423.
49. Corr S.C., Li Y., Riedel C.U., O'Toole P.W., Hill C., Gahan C.G.M. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(18):7617-7621.
50. Cotter P.D., Hill C., Ross R.P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 2005, 3(10):777-788.
51. Cui Y., Zhang C., Wang Y., Shi J., Zhang L., Ding Z., Qu X., Cui H. Class IIa Bacteriocins: diversity and new developments. Int. J. Mol. Sci. 2012, 13(12):16668-16707.
52. Dabour N., Zihler A., Kheadr E., Lacroix C., Fliss I. In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Int. J. Food Microbiol. 2009, 133(3):225-233.
53. Dabrowska K., Switala-Jelen K., Opolski A., Weber-Dabrowska B., Gorski A. Bacteriophage penetration in vertebrates. J. Appl. Microbiol. 2005, 98(1):7-13.
54. Dadachova E., Burns T., Bryan R.A., Apostolidis C., Brechbiel M.W., Nosanchuk J.D., Casadevall A., Pirofski L. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob. Agents Chemother. 2004, 48(5):1624-1629.
55. Daniel A., Euler C., Collin M., Chahales P., Gorelick K.J., Fischetti V.A. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2010, 54(4):1603-1612.
56. De Vuyst L., Leroy F. Bacteriocins from lactic acid bacteria: production, purification, and food applications. J. Mol. Microbiol. Biotechnol. 2007, 13(4):194-199.
57. Debarbieux L., Leduc D., Maura D., Morello E., Criscuolo A., Grossi O., Balloy V., Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 2010, 201(7):1096-1104.
58. Desriac F., Defer D., Bourgougnon N., Brillet B., Le Chevalier P., Fleury Y. Bacteriocin as weapons in the marine animal-associated bacteria warfare: inventory and potential applications as an aquaculture probiotic. Mar. Drugs 2010, 8(4):1153-1177.
59. Devocelle M. Targeted antimicrobial peptides. Front. Immunol. 2012, 3(309):1-4.
60. Donabedian S.M., Thal L.A., Hershberger E., Perri M.B., Chow J.W., Bartlett P., Jones R., Joyce K., Rossiter S., Gay K., Johnson J., Mackinson C., Debess E., Madden J., Angulo F., Zervos M.J. Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food. J. Clini. Microbiol. 2003, 41(3):1109-1113.
61. Donovan D.M., Dong S., Garrett W., Rousseau G.M., Moineau S., Pritchard D.G. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. Microbiol. 2006, 72(4):2988-2996.
62. Doring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008, 26(8):1011-1024.
63. Duquesne S., Destoumieux-Garzón D., Peduzzi J., Rebuffat S. Microcins, gene-encoded antibacterial peptides form enterobacteria. National Products Reports 2007, 24(4):708-734.
64. Edgar R., Friedman N., Molshanski-Mor S., Qimron U. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol. 2012, 78(3):744-751.
65. Escobar-Paramo P., Gougat-Barbera C., Hochberg M.E. Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evol. Appl. 2012, 5(6):583-592.
66. Fair R.J., Yitzhak T. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 2014, 6:25-64.
67. Falagas M.E., Karageorgopoulos D.E., Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011, 6(6):653-666.
68. Fenton M., Ross P., McAuliffe O., O'Mahony J., Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 2010, 1(1):9-16.
69. Fernández L., Delgado S., Herrero H., Maldonado A., Rodríguez J.M. The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J. Hum. Lact. 2008, 24(3):311-316.
70. Fernebro J. Fighting bacterial infections - future treatment options. Drug Resist. Updat. 2011, 14(2):125-139.
71. Fischetti V.A. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 2008, 11(5):393-400.
72. Fischetti V.A. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 2010, 300(6):357-362.
73. Fischetti V.A. Exploiting what phage have evolved to control Gram-positive pathogens. Bacteriophage 2011, 1(4):188-194.
74. Fleming A. Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenza. Br. J. Exp. Pathol. 1929, 10:226-236.
75. Freire-Moran L., Aronsson B., Manz C., Gyssens I.C., So A.D., Monnet D.L., Cars O. Critical shortage of new antibiotics in development against multidrug-resistant bacteria - time to react is now. Drug Resist. Updat. 2011, 14(2):118-124.
76. Galan J.E., Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 2006, 444(7119):567-573.
77. Gillor O., Nigro L.M., Riley M.A. Genetically engineered bacteriocins and their potential as the next generation of antimicrobials. Curr. Pharm. Des. 2005, 11(8):1067-1075.
78. Gillor O., Etzion A., Riley M.A. The dual role of bacteriocins as anti- and probiotics. Appl. Microbiol. Biotechnol. 2008, 81(4):591-606.
79. Giuliani A., Pirri G., Nicoletto S.F. Antimicrobial peptides: an overview of a promising class of therapeutics. Central Eur. J. Biol. 2007, 2(1):1-33.
80. Gladstone R.A., Jefferies J.M., Faust S.N., Clarke S.C. Continued control of pneumococcal disease in the UK - the impact of vaccination. J. Med. Microbiol. 2011, 60:1-8. 10.1099/jmm.0.020016-0.
81. Goossens H., Ferech R., Vander Stichele R., Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross national database study. Lancet 2005, 365(9459):579-587.
82. Gordon Y.J., Romanowski E.G., McDermott A.M. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 2005, 30(7):505-515.
83. Gotteland M., Andrews M., Toledo M., Muñoz L., Caceres P., Anziani A., Wittig E., Speisky H., Salazar G. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. Nutrition 2008, 24(5):421-426.
84. Granger M., van Reenen C.A., Dicks L.M. Effect of gastro-intestinal conditions on the growth of Enterococcus mundtii ST4SA, and production of bacteriocin ST4SA recorded by real-time PCR. Int. J. Food Microbiol. 2008, 123(3):277-280.
85. Gratia A. Sur un remarquable example d'antagonisme entre deux souches de colibacille. Compt. Rend. Soc. Biol. 1925, 93:1040-1042.
86. Gratia J.P. André Gratia: a forerunner in microbial and viral genetics. Genetics 2000, 156(2):471-476.
87. Gravesen A., Ramnath M., Rechinger K.B., Andersen N., Jänsch L., Héchard Y., Hastings J.W., Knøchel S. High-level resistance to class IIa bacteriocins is associated with one general mechanism in Listeria monocytogenes. Microbiology 2002, 148(8):2361-2369.
88. Gutierrez J.A., Crowder T., Rinaldo-Matthis A., Ho M.C., Almo S.C., Schramm V.L. Transition state analogs of 5'-methylthioadenosine nucleosidase disrupt quorum sensing. Nat. Chem. Biol. 2009, 5(4):251-257.
89. Hagens S., Loessner M.J. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr. Pharm. Biotechnol. 2010, 11(1):58-68.
90. Hammami R., Zouhir A., Le Lay C., Ben Hamida J., Fliss I. Bactibase second release: a database and tool platform for bacteriocin characterization. BioMed Central Microbiol. 2010, 10:22-26.
91. Hanlon G.B. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents 2007, 30(2):118-128.
92. Hermoso J.A., García J.L., García P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr. Opin. Microbiol. 2007, 10(5):461-472.
93. Hillman J.D., Mo J., McDonell E., Cvitkovitch D., Hillman C.H. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J. Appl. Microbiol. 2007, 102(5):1209-1219.
94. Hoopes J.T., Stark C.J., Kim H.A., Sussman D.J., Donovan D.M., Nelson D.C. Use of a bacteriophage lysin, PlyC as an enzyme disinfectant against Streptococcus equi. Appl. Environ. Microbiol. 2009, 75(5):1388-1394.
95. Housby J.N., Mann N.H. Phage therapy. Drug Discov. Today 2009, 14(11-12):536-540.
96. Huang E., Zhang L., Chung Y., Zheng Z., Yousef A.E. Characterization and application of enterocin RM6, a bacteriocin from Enterococcus faecalis. BioMed Res. Int. 2013, 2013:206917.
97. Hudson D.L., Layton A.N., Field T.R.,: Bowen A.J., Wolf-Watz H., Elofsson M., Stevens M.P., Galyov E.E. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents Chemother. 2007, 51(7):2631-2635.
98. Hung C.H., Kuo C.F., Wang C.H., Wu C.M., Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae - mediated liver abscesses and bacterimia in mice. Antimicrob. Agents Chemother. 2011, 55(4):1358-1365.
99. Hyman P., Abedon S.T. Bacteriophage host range and bacterial resistance. Advances in Applied Microbiology 2010, vol. 70:217-248. Elsevier Academic Press Inc., San Diego.
100. Izadpanah A., Gallo R.L. AMPs demonstrate being effective against a broad range of microorganisms, including Gram-negative and Gram-positive bacteria, fungi, and viruses. J. Am. Acad. Dermatol. 2005, 52:381-390.
101. Jacoby G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 2005, 41(2):120-126.
102. Jado I., Lopez R., Garcia E., Fenoll A., Casal J., García P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 2003, 52(6):967-973.
103. Jeevaratnam K., Jamuna M., Bawa A.S. Biological preservation of foods - Bacteriocins of lactic acid bacteria. Indian J. Biotechnol. 2005, 4:446-454.
104. Jenssen H., Hamill P., Hancock R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19(3):491-511.
105. Jeong N., Kim J.Y., Park S.C., Lee J.K., Gopal R., Yoo S., Son B.K., Hahm J.S., Park Y., Hahm K.S. Antibiotic and synergistic effect of Leu-Lys rich peptide against antibiotic resistant microorganisms isolated from patients with cholelithiasis. Biochem. Biophys. Res. Commun. 2010, 399(4):581-586.
106. Jończyk E., Klak M., Miedzybrodzki R., Górski A. The influence of external factors on bacteriophages. Folia Microbiol. (Praha) 2011, 56(3):191-200.
107. Johnsen P.J., Osterhus J.I., Sletvold H., Sørum M., Kruse H., Nielsen K., Simonsen G.S., Sundsfjord A. Persistence of animal and human glycopeptide-resistant enterococci on two Norwegian poultry farms formerly exposed to avoparcin is associated with a widespread plasmid-mediated vanA element within a polyclonal Enterococcus faecium population. Appl. Environ. Microbiol. 2005, 71(1):159-168.
108. Johnson R.P., Gyles C.L., Huff W.E., Ojha S., Huff G.R., Rath N.C., Donoghue A.M. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim. Health Res. Rev. 2008, 9(2):201-215.
109. Kaewsrichan J., Peeyananjarassri K., Kongprasertkit J. Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. Fed. Eur. Microbiol. Soc. Immunol. Med. Microbiol. 2006, 48(1):75-83.
110. Katsunuma Y., Hanazumi M., Fujisaki H., Minato H., Kataoka Y., Sawada T., Hashimoto Y., Yonemochi C. Comparison of pulsed-field gel electrophoresis patterns of antimicrobial-resistant Escherichia coli and enterococci isolates from the faeces of livestock and livestock farmers in Japan. J. Gen. Appl. Microbiol. 2008, 54(1):39-50.
111. Kaufmann G.F., Park J., Janda K.D. Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin. Biol. Ther. 2008, 8(6):719-724.
112. Kaur B., Balgir P.P., Mittu B., Kumar B., Garg N. Biomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770. BioMed Res. Int. 2013, 2013:168438.
113. Kawada-Matsuo M., Yoshida Y., Zendo T., Nagao J., Oogai Y., Nakamura Y., Sonomoto K., Nakamura N., Komatsuzawa H. Three distinct two-component systems are involved in resistance to the class I bacteriocins, nukacin ISK-1 and nisin A in Staphylococcus aureus. PLoS One 2013, 8(7):e69455.
114. Kazazic M., Nissen-Meyer J., Fimland G. Mutational analysis of the role of charged residues in target-cell binding, potency and specificity of the pediocin-like bacteriocin sakacin P. Microbiology 2002, 148(7):2019-2027.
115. Kim O.Y., Hong B.S., Park K.S., Yoon Y.J., Choi S.J., Lee W.H., Roh T.Y., Lötvall J., Kim Y.K., Gho Y.S. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J. Immunol. 2013, 190(8):4092-4102.
116. Kjos M., Salehian Z., Nes I.F., Diep D.B. An extracellular loop of the mannose phosphotransferase system component IIC is responsible for specific targeting by class IIa bacteriocins. J. Bacteriol. 2010, 192(22):5906-5913.
117. Kjos M., Nes I.F., Diep D.B. Mechanisms of resistance to bacteriocins targeting the mannose phosphotransferase system. Appl. Environ. Microbiol. 2011, 77(10):3335-3342.
118. Kosciuczuk E.M., Lisowski P., Jarczak J., Strzałkowska N., Jóźwik A., Horbańczuk J., Krzyzewski J., Zwierzchowski L., Bagnicka E. Cathelicidins: family of antimicrobial peptides. A review. Mol. Biol. Rep. 2012, 39(12):10957-10970.
119. Kristian S.A., Lauth X., Nizet V., Goetz F., Neumeister B., Peschel A., Landmann R. Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. J. Infect. Dis. 2003, 188(3):414-423.
120. Kruszewska D., Sahl H.G., Bierbaum G., Pag U., Hynes S.O., Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 2004, 54(3):648-653.
121. Kutter E., de Vos D., Gvasalia G., Alavidze Z., Gogokhia L., Kuhl S., Abedon S.T. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11(1):69-86.
122. Laverty G., Gorman S.P., Gilmore B.F. The potential of antimicrobial peptides as biocides. Int. J. Mol. Sci. 2011, 12(10):6566-6596.
123. Layton A.N., Hudson D.L., Thompson A., Hinton J.C., Stevens J.M., Galyov E.E., Stevens M.P. Salicylidene acylhydrazide-mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. Fed. Eur. Microbiol. Soc. Microbiol. Lett. 2010, 302(2):114-122.
124. Le Blay G., Lacroix C., Zihler A., Fliss I. In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett. Appl. Microbiol. 2007, 45(3):252-257.
125. Lee H., Kim H.Y. Lantibiotics, class I bactiriocins from the genus Bacillus. J. Microbiol. Biotechnol. 2011, 21(3):229-235.
126. Leung E., Weil D.E., Raviglione M., Nakatani H. The WHO policy package to combat antimicrobial resistance. Bull. World Health Organ 2011, 89(May (5)):390-392. 10.2471/BLT.11.088435.
127. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2(2):166-173.
128. Lewis K. Antibiotics: recover the lost art of drug discovery. Nature 2012, 485(7399):439-440.
129. Lewis K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 2013, 12(5):371-387.
130. Li J., Nation R.L., Milne R.W., Turnidge J.D., Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int. J. Antimicrob. Agents 2005, 25(1):11-25.
131. Ling L.L., Schneider T., Peoples A.J., Spoering A.L., Engels I., Conlon B.P., Mueller A., Schäberle T.F., Hughes D.E., Epstein S., Jones M., Lazarides L., Steadman V.A., Cohen D.R., Felix C.R., Ashley Fetterman K., Millett W.P., Nitti A.G., Zullo A.M., Chen C., Lewis K. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517(7535):455-459.
132. Liu Y.-Y., Wang Y., Walsh T.R., Yi L.-X., Zhang R., Spencer J., Doi Y., Tian G., Dong B., Huang X., Yu L.-F., Gu D., Ren H., Chen X., Lv L., He D., Zhou H., Liang Z., Liu J.-H., Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 2016, 16(2):161-168.
133. Livermore D.M. Future directions with daptomycin. J. Antimicrob. Chemother. 2008, 62(3):41-49.
134. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage 2011, 1(2):111-114.
135. Loeffler J.M., Djurkovic S., Fischetti V.A. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 2003, 71(11):6199-6204.
136. Lohans C.T., Vederas J.C. Development of class IIa bacteriocins as therapeutic agents. Int. J. Microbiol. 2012, 2012:386410.
137. Lu T.K., Collins J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(12):4629-4634.
138. Mainous A.G., Everett C.J., Post R.E., Diaz V.A., Hueston W.J. Availability of antibiotics for purchase without a prescription on the internet. Ann. Fam. Med. 2009, 7(5):431-435.
139. Manoharadas S., Witte A., Blasi U. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol. 2009, 139(1):118-123.
140. Marlovits T.C., Stebbins C.E. Type III secretion systems shape up as they ship out. Curr. Opin. Microbiol. 2010, 13(1):47-52.
141. Martínez-Júlvez M., Rojas A.L., Olekhnovich I., Espinosa A.V., Hoffman P.S., Sancho J. Structure of RdxA: an oxygen insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori. J. Fed. Eur. Biochem. Soc. 2012, 279(23):4306-4317.
142. Matsuzaki S., Rashel M., Uchiyama J., Sakurai S., Ujihara T., Kuroda M., Ikeuchi M., Tani T., Fujieda M., Wakiguchi H., Imai S. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 2005, 11(5):211-219.
143. Maura D., Debarbieux L. Bacteriophages as twenty-first century antibacterial tools for food and medicine. Appl. Microbiol. Biotechnol. 2011, 90(3):851-859.
144. May J.J., Finking R., Wiegeshoff F., Weber T.T., Bandur N., Koert U., Marahiel M.A. Inhibition of the d-alanine: d-alanyl carrier protein ligase from Bacillus subtilis increases the bacterium's susceptibility to antibiotics that target the cell wall. Fed. Eur. Biochem. Soc. J. 2005, 272(12):2993-3003.
145. McGowan S., Buckle A.M., Mitchell M.S., Hoopes J.T., Gallagher D.T., Heselpoth R.D., Shen Y., Reboul C.F., Law R.H., Fischetti V.A., Whisstock J.C., Nelson D.C. X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(31):12752-12757.
146. McInturff J.E., Wang S.J., Machleidt T., Lin T.R., Oren A., Hertz C.J., Krutzik S.R., Hart S., Zeh K., Anderson D.H., Gallo R.L., Modlin R.L., Kim J. Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes. J. Invest. Dermatol. 2005, 125(2):256-263.
147. McPhee J.B., Scott M.G., Hancock R.E. Design of host defence peptides for antimicrobial and immunity enhancing activities. Combinatorial Chem. High Throughput Screen. 2005, 8(3):257-272.
148. Meir S., Weber R., Zbinden R., Ruef C., Hasse B. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011, 39(4):333-340.
149. Merabishvili M., Pirnay J.P., Verbeken G., Chanishvili N., Tediashvili M., Lashkhi N., Glonti T., Krylov V., Mast J., Van Parys L., Lavigne R., Volckaert G., Mattheus W., Verween G., de Corte P., Rose T., Jennes S., Zizi M., de Vos D., Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009, 4(3):e4944. 10.1371/journal.pone.0004944.
150. Moayeri M., Wiggins J.F., Lindeman R.E., Leppla S.H. Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. 2006, 50(8):2658-2665.
151. Morello E., Saussereau E., Maura D., Huerre M., Touqui L., Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 2011, 6(2):e16963.
152. Mygind P.H., Fischer R.L., Schnorr K.M., Hansen M.T., Sönksen C.P., Ludvigsen S., Raventós D., Buskov S., Christensen B., De Maria L., Taboureau O., Yaver D., Elvig-Jørgensen S.G., Sørensen M.V., Christensen B.E., Kjaerulff S., Frimodt-Moller N., Lehrer R.I., Zasloff M., Kristensen H.H. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005, 437(7061):975-980.
153. Nabel G.J. Designing tomorrow's vaccines. N. Engl. J. Med. 2013, 368(6):551-560.
154. Nakatsuji T., Gallo R.L. Antimicrobial peptides: old molecules with new ideas. J. Invest. Dermatol. 2012, 132(3):887-895.
155. Nascimento I.P., Leite L.C. Recombinant vacines and the development of new vaccine strategies. Braz. J. Med. Biol. Res. 2012, 45(12):1102-1111.
156. Nelson D., Loomis L., Fischetti V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(7):4107-4112.
157. Nelson D., Schuch R., Chahales P., Zhu S., Fischetti V.A. PlyC: a multimeric bacteriophage lysin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(28):10765-10770.
158. Nichols D., Cahoon N., Trakhtenberg E.M., Pham L., Mehta A., Belanger A., Kanigan T., Lewis K., Epstein S.S. Use of ichip for high-throughput in situ cultivation of "uncultivable" microbial species. Appl. Environ. Microbiol. 2010, 76(8):2445-2450.
159. Nieves W., Asakrah S., Qazi O., Brown K.A., Kurtz J., Aucoin D.P., McLachlan J.B., Roy C.J., Morici L.A. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 2011, 29(46):8381-8389.
160. Nishant T., Sathish K.D., Arun K.R., Hima B.K., Raviteja Y. Bacteriocin producing probiotic lactic acid bacteria. J. Microbial. Biochem. Technol. 2011, 3(5):121-124.
161. Nishie M., Nagao J., Sonomoto K. Antibacterial peptides "bacteriocins": an overview of their diverse characteristics and applications. Biocontrol Sci. 2012, 17(1):1-16.
162. Nissen-Meyer J., Rogne P., Oppegard C., Haugen H.S., Kristiansen P.E. Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by gram-positive bacteria. Curr. Pharm. Biotechnol. 2009, 10(1):19-37.
163. Nitsch-Osuch A., Gyrczuk E., Wardyn A., Zycińska K., Brydak L. Antibiotic prescription practices among children with influenza. Adv. Exp. Med. Biol. 2016, 905:25-31.
164. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 2006, 8(1):11-26.
165. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011, 17(October (10)):1791-1798. 10.3201/eid1710.110655.
166. Nosanchuk J.D., Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens. Front. Microbiol. 2012, 2(283):1-6.
167. O'Flaherty S., Ross R.P., Meaney W., Fitzgerald G.F., Elbreki M.F., Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 2005, 71(4):1836-1842.
168. O'Flaherty S., Ross R.P., Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol. Rev. 2009, 33(4):801-819.
169. Obeso J.M., Martinez B., Rodriguez A., García P. Lytic activity of the recombinant staphylococcal bacteriophage phiH5 endolysin active against Staphylococcus aureus in milk. Int. J. Food Microbiol. 2008, 128(2):212-218.
170. Ojala V., Laitalainen J., Jalasvuori M. Fight evolution with evolution: plasmid-dependent phages with a wide host range prevent the spread of antibiotic resistance. Evol. Appl. 2013, 6(6):925-932.
171. Oldfield E., Feng X. Resistance-resistant antibiotics. Trends Pharmacol. Sci. 2014, 35(12):664-674.
172. Oleksiewicz M.B., Nagy G., Nagy E. Anti-bacterial monoclonal antibodies: back to the future?. Arch. Biochem. Biophys. 2012, 526(2):124-131.
173. Oppegard C., Rogne P., Emanuelsen L., Kristiansen P.E., Fimland G., Nissen-Meyer J. The two-peptide class II bacteriocins: structure, production, and mode of action. J. Mol. Microbiol. Biotechnol. 2007, 13(4):210-219.
174. Orito Y., Morita M., Hori K., Unno H., Tanji Y. Bacillus amyloliquefaciens phage endolysin can enhance permeability of Pseudomonas aeruginosa outer membrane and induce cell lysis. Appl. Microbiol. Biotechnol. 2004, 65(1):105-109.
175. Overhage J., Campisano A., Bains M., Torfs E.C., Rehm B.H., Hancock R.E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76(9):4176-4182.
176. Pang Y.P., Davis J., Wang S., Park J.G., Nambiar M.P., Schmidt J.J., Millard C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS One 2010, 5(4):e10129.
177. Papagianni M., Anastasiadou S. Pediocins: the bacteriocins of Pediococci. Sources, production, properties and applications. BioMed Central Microbial Cell Factor. 2009, 8:3-19.
178. Park S.C., Park Y., Hahm K.S. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 2011, 12(9):5971-5992.
179. Parracho H.M., Burrowes B.H., Enright M.C., McConville M.L., Harper D.R. The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 2012, 6:279-286. (Epub 2012 April 23).
180. Peters B.M., Shirtliff M.E., Jabra-Rizk M.A. Antimicrobial peptides: primeval molecules or future drugs?. PLoS Pathogens 2010, 6(10):e1001067.
181. Piddock L.V. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. 2006, 19(2):382-402.
182. Pina E., Silva M.G., Silva E.G., Uva A.S. Infecção relacionada com a prestação de cuidados de saúde: infecções da corrente sanguínea (septicemia). Revista Portuguesa de Saúde Pública 2010, 28(1):19-30.
183. Pina E., Ferreira E., Marques A., Matos B. Infecções associadas aos cuidados de saúde e segurança do doente. Revista Portuguesa de Saúde Pública 2010, 10:27-39.
184. Pirnay J., de Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., Zizi M., Laire G., Lavigne R., Huys I., van den Mooter G., Buckling A., Debarbieux L., Pouillot F., Azeredo J., Kutter E., Dublanchet A., Górski A., Adamia R. The phage therapy paradigm: pret-a-porter or sur-mesure?. Pharm. Res. 2011, 28(4):934-937.
185. Pirnay J., Verbeken G., Rose T., Jennes S., Zizi M., Huys I., Lavigne R., Merabishvili M., Vaneechoutte M., Buckling A., de Vos D. Introducing yesterday's phage therapy in today's medicine. Future Virol. 2012, 7(4):379-390.
186. Potera C. Phage renaissance: new hope against antibiotic resistance. Environ. Health Perspect. 2013, 121(2):48-53.
187. Pouillot F., Blois H., Iris F. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror. 2010, 8(2):155-169.
188. Proença D., Fernandes S., Leandro C., Silva F.A., Santos S., Lopes F., Mato R., Cavaco-Silva P., Pimentel M., São-José C. Phage endolysins with broad antimicrobial activity against Enterococcus faecalis clinical strains. Microbial Drug Resist. 2012, 18(3):322-332.
189. Pushpanathan M., Gunasekaran P., Rajendhran J. Antimicrobial peptides: versatile biological properties. Int. J. Peptides 2013, 2013. (15 pp., Article ID 675391). 10.1155/2013/675391.
190. Rajaram G., Manivasagan P., Thilagavathi B., Saravanakumar A. Purification and characterization of a bacteriocin produced by Lactobacillus lactis isolated from marine environment. Adv. J. Food Sci. Technol. 2010, 2(2):138-144.
191. Ramaswamy V., Cresence V.M., Rejitha J.S., Lekshmi M.U., Dharsana K.S., Prasad S.P., Vijila H.M. Listeria - review of epidemiology and pathogenesis. J. Microbiol. Immunol. Infect. 2007, 40(1):4-13.
192. Rang H.P., Dale M.M., Ritter J.M., Flower R.J., Henderson G. Rang & Dale's Pharmacology 2012, Elsevier, Churchill Livingstone. 7th ed.
193. Rashel M., Uchiyama J., Ujihara T., Uehara Y., Kuramoto S., Sugihara S., Yagyu K., Muraoka A., Sugai M., Hiramatsu K., Honke K., Matsuzaki S. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis. 2007, 196(8):1237-1247.
194. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 2009, 18(6):237-238.
195. Rivera J., Nakouzi A.S., Morgenstern A., Bruchertseifer F., Dadachova E., Casadevall A. Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Antimicrob. Agents Chemother. 2009, 53(11):4860-4868.
196. Rodríguez-Rubio L., Martínez B., Rodríguez A., Donovan D.M., Götz F., García P. The phage lytic proteins from the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 display multiple active catalytic domains and do not trigger staphylococcal resistance. PLoS One 2013, 8(5):e64671. 10.1371/journal.pone.0064671.
197. Romanelli R.M., Clemente W.T., Lima S.S., Rezende E.M., Martinho G.H., Paiva L.F., Neves F.A., Madeira J.G., Amâncio G.C., Lima A.S., Faria L.C., Coutinho R.I. MRSA outbreak at a transplantation unit. Braz. J. Infect. Dis. 2010, 14(1):54-59.
198. Rouveix B. Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria. J. Antimicrob. Chemother. 2007, 59(6):1208-1209.
199. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 2007, 4(4):297-305.
200. Sang Y., Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim. Health Res. Rev. 2008, 9(2):227-235.
201. Sass P., Bierbaum G. Lytic Activity of recombinant bacteriophage φ11 and φ12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 2007, 73(1):347-352.
202. Saylor C., Dadachova E., Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27(6):38-46.
203. Schmelcher M., Powell A.M., Becker S.C., Camp M.J., Donovan D.M. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 2012, 78(7):2297-2305.
204. Scholl D., Rogers S., Adhya S., Merril C.R. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 2001, 75(6):2509-2515.
205. Schuch R., Nelson D., Fischetti V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002, 418(6900):884-889.
206. Schuch R., Pelzek A.J., Raz A., Euler C.W., Ryan P.A., Winer B.Y., Farnsworth A., Bhaskaran S.S., Stebbins C.E., Xu Y., Clifford A., Bearss D.J., Vankayalapati H., Goldberg A.R., Fischetti V.A. Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One 2013, 8(4):e60754.
207. Seo M., Won H., Kim J., Mishig-Ochir T., Lee B. Antimicrobial peptides for therapeutic applications: a review. Molecules 2012, 17(10):12276-12286.
208. Settanni L., Corsetti A. Application of bacteriocins in vegetable food biopreservation. Int. J. Food Microbiol. 2008, 121(2):123-138.
209. Singh P.K., Chittpurna A., Sharma V., Patil P.B., Korpole S. Identification, purification and characterization of Laterosporulin, a novel bacteriocin produced by Brevibacillus sp Strain GI-9. PLoS One 2012, 7(3):e31498.
210. Skurnik M., Strauch E. Phage therapy: facts and fiction. Int. J. Med. Microbiol. 2006, 296(1):5-14.
211. Slaninová J., Mlsová V., Kroupová H., Alán L., Tůmová T., Monincová L., Borovičková L., Fučík V., Ceřovský V. Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. Peptides 2012, 33(1):18-26.
212. Soto C.M., Ratna B.R. Virus hybrids as nanomaterials for biotechnology. Curr. Opin. Biotechnol. 2010, 21(4):426-438.
213. Stavri M., Piddock L.J., Gibbons S. Bacterial efflux pumps from natural sources. J. Antimicrob. Chemother. 2007, 59(6):1247-1260.
214. Stojković E.A., Rothman-Denes L.B. Coliphage N4 N-acetylmuramidase defines a new family of murein hydrolases. J. Mol. Biol. 2007, 366(2):406-419.
215. Sulakvelidze A., Alavidze Z., Morrais J. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45(3):649-659.
216. Summers W.C. The strange history of phage therapy. Bacteriophage 2012, 2(2):130-133.
217. Suttmann H., Retz M., Paulsen F., Harder J., Zwergel U., Kamradt J., Wullich B., Unteregger G., Stöckle M., Lehmann J. Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol. 2008, 8:5-11.
218. Tamaki H., Zhang R., Angly F.E., Nakamura S., Hong P.Y., Yasunaga T., Kamagata Y., Liu W.T. Metagenomic analysis of DNA viruses in a wastewater treatment plant in tropical climate. Environ. Microbiol. 2012, 14(2):441-452.
219. Tanji Y., Shimada T., Fukudomi H., Miyanaga K., Nakai Y., Unno H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J. Biosci. Bioeng. 2005, 100(3):280-287.
220. Tessema G.T., Moretro T., Kohler A., Axelsson L., Naterstad K. Complex phenotypic and genotypic responses of Listeria monocytogenes strains exposed to the class IIa bacteriocin sakacin P. Appl. Environ. Microbiol. 2009, 75(22):6973-6980.
221. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn?. Int. J. Antimicrob. Agents 2009, 34(1):15-20.
222. Tominaga T., Hatakeyama Y. Development of innovative pediocin PA-1 by DNA shuffling among class IIa bacteriocins. Appl. Environ. Microbiol. 2007, 73(16):5292-5299.
223. Tsang K.Y., Luk S., Lo J.Y., Tsang T.Y., Lai S.T., Ng T.K. Hong Kong experiences the "Ultimate superbug": NDM-1 Enterobacteriaceae. Hong Kong Med. J. 2012, 18(5):439-441.
224. Vadyvaloo V., Hastings J.W., van der Merwe M.J., Rautenbach M. Membranes of class IIa bacteriocin-resistant Listeria monocytogenes cells contain increased levels of desaturated and short-acyl-chain phosphatidylglycerols. Appl. Environ. Microbiol. 2002, 68(11):5223-5230.
225. Vadyvaloo V., Arous S., Gravesen A., Héchard Y., Chauhan-Haubrock R., Hastings J.W., Rautenbach M. Cell-surface alterations in class IIa bacteriocin resistant Listeria monocytogenes strains. Microbiology 2004, 150(9):3025-3033.
226. Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. P T 2015, 40(4):277-283.
227. Viertel T.M., Ritter K., Horz H.-P. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J. Antimicrob. Chemother. 2014, 69(9):2326-2336.
228. Viswanathan V.K. Off-label abuse of antibiotics by bacteria. Gut Microbes 2014, 5(1):3-4.
229. Volozhantsev N.V., Verevkin V.V., Bannov V.A., Krasilnikova V.M., Myakinina V.P., Zhilenkov E.L., Svetoch E.A., Stern N.J., Oakley B.B., Seal B.S. The genome sequence and proteome of bacteriophage ΦCPV1 virulent for Clostridium perfringens. Virus Res. 2011, 155(2):433-439.
230. WHO Antimicrobial Resistance 2015, April 2015, Available online at. arxiv:/www.who.int.
231. Walsh T.R. New Delhi metallo-beta-lactamase-1: detection and prevention. Can. Med. Assoc. J. 2011, 183(11):1240-1241.
232. Wang I.N., Deaton J., Young R. Sizing the holin lesion with an endolysin-beta-galactosidase fusion. J. Bacteriol. 2003, 185(3):779-787.
233. Wardal E., Sadowy E., Hryniewicz W. Complex nature of enterococcal pheromone-responsive plasmids. Pol. J. Microbiol. 2010, 59(2):79-87.
234. Weber-Dabrowska B., Mulczyk M., Gorski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 2003, 35(4):1385-1386.
235. Wegener H.C. Antibiotics in animal feed and their role in resistance development. Curr. Opin. Microbiol. 2003, 6(5):439-445.
236. Weinbauer M.G. Ecology of prokaryotic viruses. FEMS Microbiol. Rev. 2004, 28(2):127-181.
237. Weisman L.E., Thackray H.M., Steinhorn R.H., Walsh W.F., Lassiter H.A., Dhanireddy R., Brozanski B.S., Palmer K.G., Trautman M.S., Escobedo M., Meissner H.C., Sasidharan P., Fretz J., Kokai-Kun J.F., Kramer W.G., Fischer G.W., Mond J.J. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011, 128(2):271-279.
238. Wijagkanalan W., Kawakami S., Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm. Res. 2011, 28(7):1500-1519.
239. Wittebole X., de Roock S., Opal S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2013, 4(8):1-10.
240. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34(4):349-357.
241. Wu H., Lu H., Huang J., Li G., Huang Q. EnzyBase: a novel database for enzybiotic studies. BMC Microbiol. 2012, 12:54. 10.1186/1471-2180-12-54.
242. Xu T., Ying J., Yao X., Song Y., Ma P., Bao B., Jiang W., Wu X., Tou H., Li P., Ren P., Fei J., Yang L., Liu Q., Xu Z., Zhou T., Ni L., Bao Q. Identification and characterization of two novel bla(KLUC) resistance genes through large-scale resistance plasmids sequencing. PLoS One 2012, 7(10):e47197.
243. Yan R., Zhao Z., He Y., Wu L., Cai D., Hong W., Wu Y., Cao Z., Zheng C., Li W. A new natural alpha-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Peptides 2011, 32(1):11-19.
244. Yang H., Liang L., Lin S., Jia S. Isolation and characterisation of a virulent AB1 of Acinetobacter baumannii. BMC Microbiol. 2010, 10:131. 10.1186/1471-2180-10-131.
245. Yeung A.T., Gellatly S.L., Hancock R.E. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci. 2011, 68(13):2161-2176.
246. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., Walsh T.R. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 2009, 53(12):5046-5054.
247. Yount N.Y., Yeaman M.R. Emerging themes and therapeutic prospects for anti-infective peptides. Ann. Rev. Pharmacol. Toxicolol. 2012, 52:337-360.
248. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415(6870):389-395.
249. Zendo T., Koga S., Shigeri Y., Nakayama J., Sonomoto K. Lactococcin Q, a novel two-peptide bacteriocin produced by Lactococcus lactis QU 4. Appl. Environ. Microbiol. 2006, 72(5):3383-3389.
250. Zimmer M., Vukov N., Scherer S., Loessner M.J. The murein hydrolase of the bacteriophage Ply 3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl. Environ. Microbiol. 2002, 68(11):5311-5317.